Baseline serum concentrations of TRAIL in early rheumatoid arthritis: Relationship with response to disease-modifying antirheumatic drugs

Paola Secchiero, Federica Corallini, Gabriella Castellino, Alessandra Bortoluzzi, Lorenzo Caruso, Serena Bugatti, Raffaella Bosco, Maurizio Montecucco, Francesco Trotta

Research output: Contribution to journalArticle

Abstract

Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)1461-1466
Number of pages6
JournalJournal of Rheumatology
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Antirheumatic Agents
Osteoprotegerin
Rheumatoid Arthritis
Serum
RANK Ligand
Joint Diseases
Rheumatoid Factor
Rheumatology
Therapeutics
Tumor Necrosis Factor-alpha
Enzyme-Linked Immunosorbent Assay
Apoptosis
Drug Therapy

Keywords

  • Disease modifying antirheumatic drugs
  • Early rheumatoid arthritis
  • Tumor necrosis factor related apoptosis inducing ligand

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Baseline serum concentrations of TRAIL in early rheumatoid arthritis : Relationship with response to disease-modifying antirheumatic drugs. / Secchiero, Paola; Corallini, Federica; Castellino, Gabriella; Bortoluzzi, Alessandra; Caruso, Lorenzo; Bugatti, Serena; Bosco, Raffaella; Montecucco, Maurizio; Trotta, Francesco.

In: Journal of Rheumatology, Vol. 37, No. 7, 07.2010, p. 1461-1466.

Research output: Contribution to journalArticle

Secchiero, Paola ; Corallini, Federica ; Castellino, Gabriella ; Bortoluzzi, Alessandra ; Caruso, Lorenzo ; Bugatti, Serena ; Bosco, Raffaella ; Montecucco, Maurizio ; Trotta, Francesco. / Baseline serum concentrations of TRAIL in early rheumatoid arthritis : Relationship with response to disease-modifying antirheumatic drugs. In: Journal of Rheumatology. 2010 ; Vol. 37, No. 7. pp. 1461-1466.
@article{3d679b4223604152af17b378b4956462,
title = "Baseline serum concentrations of TRAIL in early rheumatoid arthritis: Relationship with response to disease-modifying antirheumatic drugs",
abstract = "Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology",
keywords = "Disease modifying antirheumatic drugs, Early rheumatoid arthritis, Tumor necrosis factor related apoptosis inducing ligand",
author = "Paola Secchiero and Federica Corallini and Gabriella Castellino and Alessandra Bortoluzzi and Lorenzo Caruso and Serena Bugatti and Raffaella Bosco and Maurizio Montecucco and Francesco Trotta",
year = "2010",
month = "7",
doi = "10.3899/jrheum.091363",
language = "English",
volume = "37",
pages = "1461--1466",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "7",

}

TY - JOUR

T1 - Baseline serum concentrations of TRAIL in early rheumatoid arthritis

T2 - Relationship with response to disease-modifying antirheumatic drugs

AU - Secchiero, Paola

AU - Corallini, Federica

AU - Castellino, Gabriella

AU - Bortoluzzi, Alessandra

AU - Caruso, Lorenzo

AU - Bugatti, Serena

AU - Bosco, Raffaella

AU - Montecucco, Maurizio

AU - Trotta, Francesco

PY - 2010/7

Y1 - 2010/7

N2 - Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology

AB - Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology

KW - Disease modifying antirheumatic drugs

KW - Early rheumatoid arthritis

KW - Tumor necrosis factor related apoptosis inducing ligand

UR - http://www.scopus.com/inward/record.url?scp=77954442902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954442902&partnerID=8YFLogxK

U2 - 10.3899/jrheum.091363

DO - 10.3899/jrheum.091363

M3 - Article

C2 - 20472926

AN - SCOPUS:77954442902

VL - 37

SP - 1461

EP - 1466

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 7

ER -